Prevention of cardiovascular disease based on lipid lowering treatment: A challenge for the Mexican health system;Prevención de la enfermedad cardiovascular basada en tratamiento hipolipemiante: Un reto para el sistema de salud de México

Salud Publica de Mexico

Volumn 52, Issue SUPPL.1, 2010, Pages

  Gómez Pérez, Francisco J ^a   Rojas, Rosalba ^b   Villalpando, Salvador ^b   Barquera, Simón ^b   Rull, Juan ^a   Aguilar Salinas, Carlos A ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

Author keywords

Cholesterol; Cholesterol, HDL; Hypercholesterolemia; Hypoalphalipoproteinemia; LDL; Mexico; Triglycerides

Indexed keywords

ANTILIPEMIC AGENT;

ADULT; AGED; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIET RESTRICTION; EPIDEMIOLOGY; FEMALE; HEALTH SERVICE; HEALTH SURVEY; HUMAN; HYPERLIPIDEMIA; MALE; MEXICO; MIDDLE AGED; MOTIVATION; NUTRITION; PATIENT EDUCATION; PREVALENCE; PUBLIC HEALTH; RISK FACTOR; RURAL POPULATION; STATISTICS; URBAN POPULATION;

ADULT; AGED; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FASTING; FEMALE; GOALS; HEALTH SERVICES NEEDS AND DEMAND; HEALTH SURVEYS; HUMANS; HYPERLIPIDEMIAS; MALE; MEXICO; MIDDLE AGED; NUTRITION SURVEYS; PATIENT EDUCATION AS TOPIC; PREVALENCE; PUBLIC HEALTH; RISK FACTORS; RURAL POPULATION; SAMPLING STUDIES; URBAN POPULATION;

EID: 78349289673     PISSN: 00363634     EISSN: 16067916     Source Type: Journal    
DOI: 10.1590/s0036-36342010000700009     Document Type: Article

References (20)

1. Reckless JPD. Cost-effectiveness of statin. Curr Opinion Lipidol 2000;11:351-356.
2. Kassai B, Gueyffer F, Boissel J P, Bouttie F, Cucherat M. Absolute benefit, number needed to treat and gain of life expectancy: which efficacy indices for measuring the treatment benefit? J Clin Epidemiol 2003;56:977-982.
3. Grundy SM, Cleeman JI, Bairey-Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Arterioscler Thromb Vasc Biol 2004;24;149-161.
4. Grundy SM, Hansen B, Smith S, Cleeman JI, Kahn RA, for conference participants. Clinical management of metabolic syndrome. Report of the American Heart Association/National Heart. Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004;109:551-556.
5. Fedder D, Koro C, L'Italien G. New National Cholesterol Education program III guidelines for primary prevention lipid-lowering drug therapy. Circulation 2002;105:152-156.
6. Fletcher B, Berra K, Ades P, Braun L, Burke L, et al. Managing abnormal blood lipids. A collaborative approach. Circulation 2005;112:3184-3209.
7. Durrington P. Statin policy and target populations:evidence-based or evidence-biased. Curr Opin Lipidol 2004;15:381-386.
8. Gaw A, Packard Cj. At what level of coronary heart disease risk should statin be prescribed? Curr Opin Lipidol 2000;11:383-387.
9. Cappuccio F, Oakeshott P, Strazzullo P, Kerry S. Application of Framingham risk estimates to ethnic minorities in United Kingdom and implications for primary prevention of heart disease in general practice: cross sectional population based study. BMJ 2002;1271-1277.
10. Beswick A, Brindle P. Risk scoring in the assessment of cardiovascular risk. Curr Opinion Lipidol 2006;17:375-386.
11. Marshall T. Coronary heart disese prevention: insights from modelling incremental cost effectiveness. BMJ 2003;327:1264-1269.
12. Malik S, Wong ND, Franklin SS et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease and all causes in United States adults. Circulation 2004; 110:1245-1250.
13. Wannamethee SG, Shaper G, Lennon L, Morris R. Metabolic syndrome vs Framingham risk score for prediction of coronary heart disease, stroke and type 2 diabetes. Arch Intern Med 2005;165:2644-2650.
14. D'Agostino R, Grundy SM, Sullivan L, Wilson P for the CHD risk prediction group. Validation of the Framingham coronary heart disease prediction scores: Results of a multiple ethnic groups investigation. JAMA 2001;286:180-187.
15. Rojas R, Aguilar-Salinas CA, Gómez-Pérez FJ, Valles V, Franco A, Olaiz G, et al. Applicability of the National Cholesterol Education Program III (NCEP-III) Guidelines for treatment of dyslipidemia in a non-Caucasian population: A Mexican Nation-Wide Survey. Rev Invest Clin 2005;57:28-37.
16. Keevil J, Cullen M, Gangnon R, McBride P, Stein J. Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for diagnosis and treatment of dyslipidemia. Circulation 2007;115:1363-1370.
17. Aguilar-Salinas CA, Olaiz G, Valles V, Ríos JM, Gómez-Pérez FJ, Rull JA, et al. High prevalence of low HDL-cholesterol concentrations and mixed hyperlipidemia in a Mexican nation wide survey. J Lipid Research 2001;42:1298-1307.
18. Secretaría de Salud. Subsecretaría de Prevención y Protección de la Salud. Anuarios de morbilidad 1984-2002. México: Secretaría de Salud, 2002.
19. Barquera S, Flores M, Olaiz-Fernández G, Monterrubio E, Villalpando S, González C, et al. Dyslipidemias and obesity in Mexico. Salud Publica Mex 2007;49 suppl 3:S338-S347.
20. Córdova-Villalobos JA, Barriguete-Meléndez JA, Lara-Esqueda A, Barquera S, Rosas-Peralta M, Hernández-Avila M, et al. Chronic non-communicable diseases in Mexico: epidemiologic synopsis and integral prevention. Salud Publica Mex 2008;50:419-427.